ATXI - アベニュ―・セラピュ―ティクス (Avenue Therapeutics Inc.) アベニュ―・セラピュ―ティクス

 ATXIのチャート


 ATXIの企業情報

symbol ATXI
会社名 Avenue Therapeutics Inc (アベニュ―・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 Avenue Therapeutics Inc. is a pharmaceutical company. The Company is engaged in acquiring licensing developing and commercializing products principally for use in the acute or intensive care hospital setting. Its product candidate is intravenous (IV) Tramadol an intravenous formulation of tramadol hydrochloride (HCl) for the management of moderate to moderately severe postoperative pain. Tramadol a synthetic dual-acting opioid is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Tramadol is also combined with acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDS) in clinical practice. During the year ending December 31 2016 the Company had completed a pharmacokinetics (PK) study for IV Tramadol in healthy volunteers.   アベニュ―・セラピュ―ティクスは米国の専門医薬品企業。主に手術後の中程度から重度の疼痛緩和に特化した医薬品の開発・商品化に従事する。合成二重作用性オピオイドで有効性と安全性のあるトラマド―ルHCIの臨床デ―タを活用し、トラマド―ルHCI静脈内製剤の開発に焦点を当てる。本社はニューヨーク。   Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.
本社所在地 2 Gansevoort Street 9th Floor New York NY 10014 USA
代表者氏名
代表者役職名
電話番号 +1 781-652-4500
設立年月日 42125
市場名 NASDAQ Small Cap
ipoyear 2017年
従業員数
url www.avenuetx.com
nasdaq_url https://www.nasdaq.com/symbol/atxi
adr_tso
EBITDA EBITDA(百万ドル) -24.27900
終値(lastsale) 2.36
時価総額(marketcap) 24908431.2
時価総額 時価総額(百万ドル) 26.38605
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 17.44605
当期純利益 当期純利益(百万ドル) -24.22500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Avenue Therapeutics Inc revenues was not reported. Net loss increased from $3.1M to $15M. Higher net loss reflects Research and development increase from $580K to $13.2M (expense) General and administrative increase of 15% to $1.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.37 to -$1.48.

 ATXIのテクニカル分析


 ATXIのニュース

   Is Avenue Therapeutics (ATXI) Stock Outpacing Its Medical Peers This Year?  2020/05/27 15:30:18 Zacks Investment Research
Is (ATXI) Outperforming Other Medical Stocks This Year?
   How Avenue (ATXI) Stock Stands Out in a Strong Industry  2020/05/26 12:54:00 Zacks Investment Research
Avenue (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Why Avenue Therapeutics (ATXI) Stock Might be a Great Pick  2020/04/23 13:14:00 Zacks Investment Research
Avenue Therapeutics (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's Why  2020/04/16 16:00:05 Zacks Investment Research
Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
   Avenue Therapeutics (ATXI) Hits All-time High, Up 56% So Far This Month  2019/12/30 01:17:00 RTT News
Shares of Avenue Therapeutics Inc. (ATXI), which closed at an all-time high of $9.22, have gained 56% so far this month..
   Is Avenue Therapeutics (ATXI) Stock Outpacing Its Medical Peers This Year?  2020/05/27 15:30:18 Zacks Investment Research
Is (ATXI) Outperforming Other Medical Stocks This Year?
   How Avenue (ATXI) Stock Stands Out in a Strong Industry  2020/05/26 12:54:00 Zacks Investment Research
Avenue (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Why Avenue Therapeutics (ATXI) Stock Might be a Great Pick  2020/04/23 13:14:00 Zacks Investment Research
Avenue Therapeutics (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's Why  2020/04/16 16:00:05 Zacks Investment Research
Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
   Avenue Therapeutics (ATXI) Hits All-time High, Up 56% So Far This Month  2019/12/30 01:17:00 RTT News
Shares of Avenue Therapeutics Inc. (ATXI), which closed at an all-time high of $9.22, have gained 56% so far this month..
   Why Avenue Therapeutics (ATXI) Stock Might be a Great Pick  2020/04/23 13:14:00 Zacks Investment Research
Avenue Therapeutics (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   Avenue Therapeutics, Inc. (ATXI) Upgraded to Strong Buy: Here's Why  2020/04/16 16:00:05 Zacks Investment Research
Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
   Avenue Therapeutics (ATXI) Hits All-time High, Up 56% So Far This Month  2019/12/30 01:17:00 RTT News
Shares of Avenue Therapeutics Inc. (ATXI), which closed at an all-time high of $9.22, have gained 56% so far this month..
   The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer  2019/12/13 13:10:02 Benzinga Feeds
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 12.) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ) (received approval for its bone-building osteoporosis drug in the U.S.) Aprea Therapeutics Inc (NASDAQ: APRE ) Aptose Biosciences Inc (NASDAQ: APTO ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) Avenue Therapeutics Inc (NASDAQ: ATXI ) (submitted the NDA for intravenous tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting) Bausch Health Companies Inc (NYSE: BHC ) (reacted to upgrade to Overweight rating by JPMorgan) BioNTech SE – ADR (NASDAQ: BNTX ) Bio-Rad Laboratories, Inc. Class A (NYSE: BIO ) Boston Scientific Corporation (NYSE: BSX ) Bristol-Myers Squibb Co (NYSE: BMY ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Eidos Therapeutics Inc (NASDAQ: EIDX ) ESSA Pharma Inc (NASDAQ: EPIX ) Flexion Therapeutics Inc (NASDAQ: FLXN ) Forty Seven Inc (NASDAQ: FTSV ) Globus Medical Inc (NYSE: GMED ) (reacted to upgrade to Overweight by Wells Fargo Securities) Gossamer Bio Inc (NASDAQ: GOSS ) Hologic, Inc.
   Avenue Therapeutics misses by $0.39  2019/05/13 11:35:47 Seeking Alpha

 関連キーワード  (医薬品 米国株 アベニュ―・セラピュ―ティクス ATXI Avenue Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)